Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Recent analyst updates for three high-yielding healthcare stocks reveal mixed sentiment. DENTSPLY SIRONA (XRAY), yielding 4.98%, saw price target reductions from UBS (to $23) and Stifel (to $17) ahead of its Q3 earnings call. Merck & Co (MRK), with a 3.74% yield, received a price target increase from Citigroup (to $95) following better-than-expected quarterly earnings, though Wells Fargo lowered its target to $90. Viatris (VTRS), yielding 4.67%, also experienced price target cuts from Piper Sandler (to $10) and B of A Securities (to $10) prior to its upcoming Q3 results.

Analysis

The healthcare sector's high-yielding stocks are presenting a mixed outlook, as evidenced by recent analyst revisions. While investors often seek dividend-paying companies like DENTSPLY SIRONA (XRAY), Merck & Co (MRK), and Viatris (VTRS) during turbulent markets, recent analyst actions reflect varied prospects for these specific names. The overall sentiment across these three stocks is mixed, with a slight negative bias, as indicated by a general sentiment score of -0.15.

DENTSPLY SIRONA (XRAY), with a 4.98% dividend yield, faces downward price target revisions from both UBS (to $23) and Stifel (to $17) ahead of its Q3 earnings call on November 6. Similarly, Viatris (VTRS), yielding 4.67%, saw significant price target cuts from Piper Sandler (to $10) and B of A Securities (to $10) prior to its own Q3 results on the same date. These revisions suggest potential concerns regarding future performance for both companies.

In contrast, Merck & Co (MRK), offering a 3.74% dividend yield, received a positive sentiment boost (0.5 per-ticker sentiment) following better-than-expected quarterly earnings. Citigroup reinstated a Neutral rating and raised its price target from $84 to $95, despite Wells Fargo simultaneously lowering its target from $97 to $90. The positive earnings report appears to be a key driver for the more favorable analyst action from Citigroup.

Key Decisions for Investors

• Investors should exercise caution and closely monitor the upcoming Q3 earnings reports on November 6 for DENTSPLY SIRONA and Viatris, given the recent downward price target revisions.
• Merck & Co's better-than-expected earnings and subsequent price target increase from Citigroup suggest a more stable outlook, warranting further investigation into its fundamentals and growth drivers.
• Consider the varying analyst sentiments and upcoming corporate earnings as critical factors when evaluating these high-yield healthcare stocks, especially in the context of market turbulence.